>>Description of the research protocol "QoLANA"

Belgian prospective product registry to assess the use of cabazitaxel (Jevtana®) in Combination with oral Prednisone (or prednisolone) in real-life for the treatment of metastatic Castration Resistant Prostate Cancer patients
Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Urologie
Brugmann identifier : QoLANA
EudraCT identifier : B079201214948
ClinicalTrials.gov identifier : NCT02485691


Involved department : Hemato-oncology
Principal investigator : Efira
Sponsor : Sanofi
Contact : Clinical Research Unit

>This protocol was approved by the Bordet ethics committee.